DOI: https://doi.org/10.15368/theses.2013.214
Available at: https://digitalcommons.calpoly.edu/theses/1134
Date of Award
12-2013
Degree Name
MS in Polymers and Coatings
Department/Program
Chemistry & Biochemistry
Advisor
Raymond Fernando
Abstract
Glaucoma is the leading cause of blindness in the United States accounting for 9-12% of all cases of blindness. Currently, the front line treatment for glaucoma are prostaglandins that may have to be taken up to several times a day. Even with proper treatment, roughly 11% of the patients using the treatment are non-compliant and lose their vision. In this project, ForSight Laboratories has developed a pharmaceutical drug delivering implant with the capability of sustaining long-term release of a prostaglandin as a new way to treat the condition. This project reports the product development of a polymer drug matrix with a controlled release in order to better treat glaucoma. Accompanying product development, a mathematical model was created in order to strengthen the understanding of the dosage profile and to predict long term dosages.
Included in
Biomedical Devices and Instrumentation Commons, Pharmaceutical Preparations Commons, Polymer Chemistry Commons